Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

OSENI

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

Standard Dose
EQ 12.5MG BASE;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview OSENI is listed in Drugs@FDA under application 022426 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 12.5MG BASE;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor TAKEDA PHARMS USA Submission history Latest submission status date: 2024-06-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview OSENI is listed in Drugs@FDA under application 022426 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 12.5MG BASE;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor TAKEDA PHARMS USA Submission history Latest submission status date: 2024-06-28 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.